ArticleCellular and molecular life sciences : CMLS2025
Epigenetic regulation of TIPE3 in nasopharyngeal carcinoma and its impact on the hedgehog signaling pathway.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TIPE3 in Cancer: A Multifaceted Regulator of Tumorigenesis, Therapeutic Resistance, and Clinical Outcomes.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the epigenetic regulation of TIPE3 in nasopharyngeal carcinoma (NPC) and its role in tumor progression, with a focus on enhancer elements and associated histone modifications, as well as the involvement of the Hedgehog signaling pathway.
methodsThe regulation of TIPE3 was explored through chromatin immunoprecipitation (ChIP) assays to identify histone modifications, specifically H3K27ac and H3K4me3, associated with enhancer elements upstream of the TIPE3 promoter. CRISPR-Cas9 technology was employed to delete these enhancer regions in NPC cell lines. The effects on TIPE3 expression, cell proliferation, and metastasis were assessed both in vitro and in vivo. Additionally, the roles of the histone-modifying enzymes KAT2A and SETD7 in modulating these enhancer marks were examined. The activation of the Hedgehog signaling pathway by TIPE3 was also investigated.
resultsTIPE3 was found to be regulated by enhancer elements marked by H3K27ac and H3K4me3. Deletion of these enhancers resulted in significant downregulation of TIPE3, leading to reduced proliferation and metastasis of NPC cells. KAT2A and SETD7 were identified as critical regulators of TIPE3 expression, acting through these enhancer-associated histone modifications. Moreover, TIPE3 was shown to activate the Hedgehog signaling pathway, contributing to NPC progression.
conclusionThe study reveals that TIPE3 is epigenetically regulated by enhancer elements, which are modulated by KAT2A and SETD7, and that TIPE3 promotes NPC progression through activation of the Hedgehog signaling pathway. These findings suggest that targeting the enhancer-mediated regulation of TIPE3 and the associated signaling pathways could offer new therapeutic strategies for NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.